Therefore, although Aβ-targeted therapies, tau-associated therapies, and anti-inflammatory drugs have been developed to focus on the molecular pathogenesis underlying AD [5–7], an effective treatment has not been established. The gene discussed is MAPT; the disease is Alzheimer disease.